ERBB2 and breast cancer: On 15 November 2013, trastuzumab emtansine (T-DM1, Kadcyla®) was approved in the European Union for the treatment of adult patients with HER2-positive, locally advanced or metastatic BC who had previously received trastuzumab and a taxane, based on a median survival gain of 5.8 months.